Logo image of PCVX

VAXCYTE INC (PCVX) Stock Fundamental Analysis

USA - NASDAQ:PCVX - US92243G1085 - Common Stock

45.48 USD
+1.96 (+4.5%)
Last: 10/30/2025, 2:38:02 PM
Fundamental Rating

3

Taking everything into account, PCVX scores 3 out of 10 in our fundamental rating. PCVX was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PCVX as it has an excellent financial health rating, but there are worries on the profitability. PCVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PCVX has reported negative net income.
PCVX had a negative operating cash flow in the past year.
In the past 5 years PCVX always reported negative net income.
PCVX had a negative operating cash flow in each of the past 5 years.
PCVX Yearly Net Income VS EBIT VS OCF VS FCFPCVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

PCVX has a Return On Assets of -16.56%. This is in the better half of the industry: PCVX outperforms 79.96% of its industry peers.
The Return On Equity of PCVX (-17.83%) is better than 85.77% of its industry peers.
Industry RankSector Rank
ROA -16.56%
ROE -17.83%
ROIC N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
PCVX Yearly ROA, ROE, ROICPCVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

PCVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCVX Yearly Profit, Operating, Gross MarginsPCVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

PCVX has more shares outstanding than it did 1 year ago.
PCVX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PCVX Yearly Shares OutstandingPCVX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCVX Yearly Total Debt VS Total AssetsPCVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 13.63 indicates that PCVX is not in any danger for bankruptcy at the moment.
The Altman-Z score of PCVX (13.63) is better than 85.77% of its industry peers.
PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.63
ROIC/WACCN/A
WACCN/A
PCVX Yearly LT Debt VS Equity VS FCFPCVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 11.11 indicates that PCVX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 11.11, PCVX belongs to the best of the industry, outperforming 83.90% of the companies in the same industry.
A Quick Ratio of 11.11 indicates that PCVX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 11.11, PCVX belongs to the top of the industry, outperforming 83.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.11
Quick Ratio 11.11
PCVX Yearly Current Assets VS Current LiabilitesPCVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

1

3. Growth

3.1 Past

PCVX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.31%, which is quite good.
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.15% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-36.41%
EPS Next 2Y-25.34%
EPS Next 3Y-18.83%
EPS Next 5Y8.15%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCVX Yearly Revenue VS EstimatesPCVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2027 2028 2029 2030 2031 2032 1B 2B 3B
PCVX Yearly EPS VS EstimatesPCVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PCVX. In the last year negative earnings were reported.
Also next year PCVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCVX Price Earnings VS Forward Price EarningsPCVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCVX Per share dataPCVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

A cheap valuation may be justified as PCVX's earnings are expected to decrease with -18.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.34%
EPS Next 3Y-18.83%

More info and screens

0

5. Dividend

5.1 Amount

PCVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXCYTE INC

NASDAQ:PCVX (10/30/2025, 2:38:02 PM)

45.48

+1.96 (+4.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10
Inst Owners113.56%
Inst Owner Change0.04%
Ins Owners0.67%
Ins Owner Change-1.09%
Market Cap5.90B
Revenue(TTM)N/A
Net Income(TTM)-547495000
Analysts85.88
Price Target101.24 (122.6%)
Short Float %7.8%
Short Ratio5.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.32%
Min EPS beat(2)-2.1%
Max EPS beat(2)2.74%
EPS beat(4)3
Avg EPS beat(4)10.46%
Min EPS beat(4)-2.1%
Max EPS beat(4)28.3%
EPS beat(8)4
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-0.3%
EPS beat(16)8
Avg EPS beat(16)-0.72%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-21.07%
EPS NQ rev (1m)2.58%
EPS NQ rev (3m)-3.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.21%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.92
P/tB 1.92
EV/EBITDA N/A
EPS(TTM)-4.1
EYN/A
EPS(NY)-5.96
Fwd EYN/A
FCF(TTM)-4.34
FCFYN/A
OCF(TTM)-3.54
OCFYN/A
SpS0
BVpS23.66
TBVpS23.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.56%
ROE -17.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 997.95%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.11
Quick Ratio 11.11
Altman-Z 13.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1359.67%
Cap/Depr(5y)905.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10.91%
EPS Next Y-36.41%
EPS Next 2Y-25.34%
EPS Next 3Y-18.83%
EPS Next 5Y8.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-38.24%
EBIT Next 3Y-17.11%
EBIT Next 5YN/A
FCF growth 1Y-156.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.32%
OCF growth 3YN/A
OCF growth 5YN/A

VAXCYTE INC / PCVX FAQ

Can you provide the ChartMill fundamental rating for VAXCYTE INC?

ChartMill assigns a fundamental rating of 3 / 10 to PCVX.


Can you provide the valuation status for VAXCYTE INC?

ChartMill assigns a valuation rating of 0 / 10 to VAXCYTE INC (PCVX). This can be considered as Overvalued.


Can you provide the profitability details for VAXCYTE INC?

VAXCYTE INC (PCVX) has a profitability rating of 1 / 10.


What is the expected EPS growth for VAXCYTE INC (PCVX) stock?

The Earnings per Share (EPS) of VAXCYTE INC (PCVX) is expected to decline by -36.41% in the next year.